"The voice for cancer physicians and their patients in Massachusetts."

  • Home
  • Resources
  • FDA Approvals
  • FDA grants accelerated approval to sacituzumab govitecan-hziy (TRODELVY) for metastatic triple negative breast cancer

FDA grants accelerated approval to sacituzumab govitecan-hziy (TRODELVY) for metastatic triple negative breast cancer

23 Apr 2020 10:48 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration granted accelerated approval to sacituzumab govitecan-hziy (TRODELVY, Immunomedics, Inc.) for adult patients with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic disease. Read full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software